ASH 2021 | CAR-T for CLL
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses the use of CAR-T for treating patients with chronic lymphocytic leukemia (CLL), including exciting new directions for the field and challenges that are still to be overcome. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Transcript (edited for clarity)
I think in CLL, we have some good studies in CAR-T, but there’s several different cell products. There’s also in development new CAR -T targets, so not just the anti-CD19 CAR-T that was the first type developed, but there’s going to be other things that they get the T-cells to target, that might be useful in CLL. And there’s still some challenges like initially, manufacturing the CAR-T’s was a challenge in people with CLL, because they have changes in their T-cells, just because of having the CLL population...
I think in CLL, we have some good studies in CAR-T, but there’s several different cell products. There’s also in development new CAR -T targets, so not just the anti-CD19 CAR-T that was the first type developed, but there’s going to be other things that they get the T-cells to target, that might be useful in CLL. And there’s still some challenges like initially, manufacturing the CAR-T’s was a challenge in people with CLL, because they have changes in their T-cells, just because of having the CLL population.
So, most of the data in CAR-T for CLL is limited to Phase I or smaller studies, and you do get people with a really durable benefit. And I think we’ll just get better and better at using CAR-T. So, it’s one of those things where it’s an excellent option to refer people for CAR-T trials, if they’re appropriate for it. And I just really look forward over the next couple years to see how this sorts out as a field, for which products end up being best, and which patients are most suitable to get it.
Read more...
